Guanfacine Extended-Release Shows Symptom and Functioning Improvements in Diverse ADHD Youth
Study Overview
A recent retrospective chart review explored the effects of guanfacine extended-release (GXR) on children and adolescents diagnosed with attention-deficit/hyperactivity disorder (ADHD), including those with additional neurodevelopmental or psychiatric conditions. The study aimed to assess changes in ADHD symptoms and overall functioning following GXR treatment in a real-world clinical setting.
Participant Characteristics and Treatment Details
The analysis included 38 patients aged 6 to 18 years, of whom approximately three-quarters were male. All participants had ADHD, and nearly two-thirds (63.2%) also had a diagnosis of autism spectrum disorder (ASD). The average final dose of GXR, adjusted for weight, was 0.05 mg/kg/day.
Symptom and Functioning Outcomes
Among 33 patients who continued GXR treatment for at least three months and had follow-up assessments between weeks 4 and 12, notable improvements were observed. Median Clinical Global Impression-Severity (CGI-S) scores decreased from 5 (markedly ill) to 3 (mildly ill), indicating symptom reduction. Additionally, Global Assessment Scale (GAS) scores increased from 55 to 75, reflecting enhanced overall functioning.
Specific ADHD symptom domains showed improvement, particularly attention deficits, hyperactivity/impulsivity, and oppositional defiant behaviors, as measured by the Turgay scale.
Tolerability and Adverse Effects
Adverse effects were reported in about 29% of patients, with restlessness being the most common. Some patients discontinued GXR due to these side effects.
Context and Considerations
This study provides preliminary evidence supporting the potential benefits of GXR in a diagnostically diverse pediatric ADHD population, including those with comorbid ASD. However, the retrospective design, absence of a control group, small sample size, and concurrent use of other medications limit the strength of conclusions. These findings should be interpreted as early real-world observations rather than definitive evidence.
Implications for Families
For families managing ADHD with or without additional neurodevelopmental diagnoses, GXR may offer symptom relief and improved daily functioning. Nonetheless, monitoring for side effects is important, and treatment decisions should be made collaboratively with healthcare providers considering individual needs and responses.
For more detailed information, see the original study here.
Download the images in this article
